Table 6.

Self-Reported Adherence of Study Treatment After First-line Virologic Failure and Association With Virologic Suppression (HIV-1 RNA <400 Copies/mL) at Week 24 After First-line Virologic Failure for Participants Remaining on the First-line Regimen

Adherence Within the Past 4 d	No.	Suppression Rate	Univariate Analysisa		Adjusted Analysisb
			Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
100%	84	63 (75%)	Reference level	Reference level
<100%	35	19 (54%)	0.43 (.19–.99)	.046	0.38 (.15–.97)	.044
Not on ART	7	1 (14%)	0.07 (.01–.58)	.014	0.06 (.01–.59)	.016

Abbreviations: ACTG, AIDS Clinical Trials Group; ART, antiretroviral therapy; CI, confidence interval; HIV-1, human immunodeficiency virus type 1; OR, odds ratio.

^a Both univariate and adjusted analysis was stratified by ACTG study.

^b Analysis was adjusted by whether achieving HIV-1 RNA <400 copies/mL at any time prior to initial failure and whether HIV-1 RNA at first-line virologic failure <10 000 copies/mL. In this model, achieving HIV-1 RNA <400 copies/mL at any time prior to initial failure remained significant (odds ratio [OR], 5.01 [95% CI, 1.77–14.24]; P = .002), but not HIV-1 RNA <10 000 copies/mL at the time of virologic failure (OR, 2.41 [95% CI, .81–5.98]; P = .12).